| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
Decoglurant (Ro-4995819, Ro4995819, Ro 4995819) is a novel and potent negative allosteric modulator of the mGlu2 and mGlu3 receptors being developed as an adjunctive treatment modality for major depressive disorder.
| Targets |
Decoglurant (RG1578/RO4995819) is a negative allosteric modulator (NAM) of metabotropic glutamate receptors 2 and 3 (mGlu2/mGlu3 receptors). [1]
|
|---|---|
| ln Vivo |
In preclinical models, Decoglurant demonstrated rapid antidepressant-like effects by modulating glutamate/GABA neurotransmission, consistent with the mechanism of other mGlu2/3 antagonists. [1]
Clinical studies indicated that Decoglurant (5–15 mg/day) induced rapid changes in synaptic plasticity markers (e.g., BDNF, mTOR) within 24 hours in depressed patients, supporting its rapid-acting potential. [1] Clinical Trial (Phase II): Decoglurant was evaluated in a randomized, double-blind, placebo-controlled trial (NCT01457677) for major depressive disorder (MDD). Patients received daily oral doses (1.5 mg, 5 mg, 15 mg) or placebo for 6 weeks. [1] The study failed to meet its primary endpoint (change in MADRS score at Day 42), though subgroup analyses suggested efficacy in severely depressed patients (MADRS ≥30). [1] |
| ADME/Pharmacokinetics |
Decoglurant showed dose-proportional exposure following oral administration in humans, with a half-life (t1/2) supporting once-daily dosing. [1]
It exhibited good blood-brain barrier penetration in preclinical species, consistent with its CNS target engagement. [1] |
| Toxicity/Toxicokinetics |
Decoglurant showed dose-proportional exposure following oral administration in humans, with a half-life (t1/2) supporting once-daily dosing. [1]
It exhibited good blood-brain barrier penetration in preclinical species, consistent with its CNS target engagement. [1] |
| References | |
| Additional Infomation |
Decoglurant has been used in trials studying the treatment of Major Depressive Disorder.
Decoglurant was developed as a rapid-acting antidepressant targeting glutamate dysregulation, distinct from monoamine-based therapies. Its mechanism involves disinhibition of glutamate release via mGlu2/3 blockade. [1] Despite negative Phase II results, it contributed to validating mGlu2/3 modulation as a therapeutic strategy for treatment-resistant depression. [1] |
| Molecular Formula |
C21H11F6N5
|
|---|---|
| Molecular Weight |
447.335964441299
|
| Exact Mass |
447.092
|
| Elemental Analysis |
C, 56.38; H, 2.48; F, 25.48; N, 15.66
|
| CAS # |
911115-16-7
|
| PubChem CID |
71533696
|
| Appearance |
Orange to red solid powder
|
| LogP |
4.741
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
32
|
| Complexity |
720
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
FC(C1C=CC(C2C=C(C(F)(F)F)N3C(=C(C=N3)C#CC3C=CC(N)=NC=3)N=2)=CC=1)(F)F
|
| InChi Key |
DMJHZVARRXJSEG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H11F6N5/c22-20(23,24)15-6-4-13(5-7-15)16-9-17(21(25,26)27)32-19(31-16)14(11-30-32)3-1-12-2-8-18(28)29-10-12/h2,4-11H,(H2,28,29)
|
| Chemical Name |
5-[2-[7-(trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]ethynyl]pyridin-2-amine
|
| Synonyms |
Ro4995819; Ro4995819; Decoglurant; 911115-16-7; 5-((7-(Trifluoromethyl)-5-(4-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)ethynyl)pyridin-2-amine; 5VX4P0JKC5; 5-[2-[7-(trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]ethynyl]pyridin-2-amine; RO4995,819; RO-4995,819; UNII-5VX4P0JKC5; Ro-4995819
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~558.86 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.65 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2354 mL | 11.1772 mL | 22.3544 mL | |
| 5 mM | 0.4471 mL | 2.2354 mL | 4.4709 mL | |
| 10 mM | 0.2235 mL | 1.1177 mL | 2.2354 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
